

Key Figures (IFRS)

MorphoSys Group (in million €, if not stated otherwise)

	12/31/17	12/31/16	12/31/15	12/31/14	12/31/13	12/31/12	12/31/11	12/31/10	12/31/09	12/31/08
RESULTS¹										
Revenues	66.8	49.7	106.2	64.0	78.0	51.9	82.1	87.0	81.0	71.6
Cost of Goods Sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3	6.7	7.1
R&D Expenses	116.8	95.7	78.7	56.0	49.2	37.7	55.9	46.9	39.0	27.6
SG&A Expenses	17.0	14.1	15.1	14.1	18.8	12.1	14.9	23.2	23.9	20.5
Personnel Expenses (Excluding Stock-Based Compensation)	37.1	33.7	32.4	26.7	27.4	24.1	27.7	29.6	26.1	21.5
Capital Expenditure	13.1	2.9	8.8	20.5	5.6	1.8	2.9	13.8	3.8	3.8
Depreciation of Tangible Assets	2.0	1.8	1.5	1.4	1.5	1.7	1.7	2.1	1.6	1.5
Amortization of Intangible Assets	2.1	2.0	1.9	2.7	3.3	3.5	3.8	4.0	3.8	4.8
EBIT	(67.6)	(59.9)	17.2	(5.9)	9.9	2.5	9.8	13.1	12.8	16.5
Net Profit/(Loss)	(69.8)	(60.4)	14.9	(3.0)	13.3	1.9	8.2	9.2	9.0	13.2
Net Profit/(Loss) from Discontinued Operations	-	-	-	-	6.0	(0.4)	0.0	-	-	-
BALANCE SHEET										
Total Assets	415.4	463.6	400.1	426.5	447.7	224.3	228.4	209.8	206.1	203.3
Cash, Marketable Securities and Other Financial Assets	312.2	359.5	298.4	352.8	390.7	135.7	134.4	108.4	135.1	137.9
Intangible Assets	67.8	67.9	79.6	46.0	35.1	35.0	66.0	69.2	17.4	19.7
Total Liabilities	56.7	48.1	37.3	77.7	95.5	22.3	31.3	23.9	32.2	41.3
Stockholders' Equity	359.0	415.5	362.7	348.8	352.1	202.0	197.1	185.9	173.9	162.0
Equity Ratio (in %)	86%	90%	91%	82%	79%	90%	86%	89%	84%	80%
MORPHOSYS SHARE										
Number of Shares Issued	29,420,785	29,159,770	26,537,682	26,456,834	26,220,882	23,358,228	23,112,167	22,890,252	22,660,557	22,478,787
Group Earnings/(Loss) per Share, Basic and Diluted (in €)	(2.41)	(2.28)	0.57	(0.12)	0.54	0.08	0.36	0.40	0.40	0.59
Dividend (in €)	-	-	-	-	-	-	-	-	-	-
Share Price (in €)	76.58	48.75	57.65	76.63	55.85	29.30	17.53	18.53	17.04	18.75
PERSONNEL DATA										
Total Group Employees (Number ²)	326	345	365	329	299	421	446	464	404	334

¹ Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the AbD Serotec segment, for the years 2013, 2012 and 2011, revenues, income and expenses in connection with the transaction are shown in the line item "Net Profit/(Loss) from Discontinued Operations." All other line items consist of amounts from continuing operations.

² 2007 to 2012 including employees from the discontinued operations of AbD Serotec.